These articles primarily analyzed asparaginase therapy in ALL (n=23) with a smaller number reporting on AML (n=3), chronic myeloid leukemia in blast phase (n=1), and non-Hodgkin’s lymphoma (n=1). This evidence concerns the gene ASPG and chronic myelogenous leukemia, BCR-ABL1 positive.